Charles River Laboratories CRL Equity Method Investments
Equity Method Investments at other companies
Other financials
Where this comes from
Reported directly by Charles River Laboratories in its filing.
Tagged under the XBRL concept us-gaap:EquityMethodInvestments.
The official record: Charles River Laboratories’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Charles River Laboratories's equity method investments.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Charles River Laboratories's equity method investments?
- Charles River Laboratories (CRL) reported equity method investments of $209.72M in Q1 2026.
- How has Charles River Laboratories's equity method investments changed year-over-year?
- Charles River Laboratories's equity method investments decreased by 2.0% year-over-year, from $214.03M to $209.72M.
- What is the long-term trend for Charles River Laboratories's equity method investments?
- Over 5 years (2020 to 2025), Charles River Laboratories's equity method investments has grown at a 53.0% compound annual growth rate (CAGR), from $24.7M to $206.97M.
- What does equity method investments mean?
- Investments in other companies where the firm has significant influence but not full control.
- How do you interpret equity method investments?
- Growth in this balance reflects strategic expansion into new markets or technologies through partnerships.
- How does equity method investments compare across companies?
- Common in the life sciences sector as firms seek to gain exposure to innovation through minority stakes.